Citations

Clear

3030 citation(s) found for "Susan, M".

Sweating the Little Things: Tourniquet Application Efficacy in Two Models of Pediatric Limb Circumference
Sherif, Nibras El-, Lowndes, Bethany R. , Franz, Walter B., Belau, Steven, Sztajnkrycer, Matthew D. , El-Sherif, Nibras, Lowndes, Bethany, Franz, Walter, Hallbeck, M. Susan

Mayo Clinic

Military Medicine | March 22, 2019 | Volume: 184 | Issue: Supplement_1 | Pages: 361-366

10.1093/milmed/usy283 | PMID 30901457 Get It

AbstractBackgroundCurrent military recommendations include the use of tourniquets (TQ) in appropriate pediatric trauma patients. Although the utility of TQs has been well documented in adult patients, the efficacy of TQ application in pediatric patients is less clear. The current study attempted to identify physical constraints for TQ use in two simulated pediatric limb models.MethodsFive different TQ (Combat Application Tourniquet (CAT) Generation 6 and Generation 7, SOFTT (SOF Tactical Tourniquet), SOFTT-W (SOF Tactical Tourniquet – Wide), SWAT-T (Stretch Wrap and Tuck – Tourniquet) and a trauma dressing were evaluated in two simulated pediatric limb models. Model one employed four cardiopulmonary resuscitation (CPR) manikins simulating infant (Simulaids SaniBaby), 1 year (Gaumard HAL S3004), and 5 years (Laerdal Resusci Junior, Gaumard HAL S3005). Model two utilized polyvinyl chloride (PVC) piping with circumferences ranging from 4.25” to 16.5”. Specific end-points included tightness of the TQ and ability to secure the windlass (where applicable).ResultsIn both models, the ability to successfully apply and secure the TQ depended upon the simulated limb circumference. In the 1-year-old CPR manikin, all windlass TQs failed to tighten on the upper extremity, while all TQs successfully tightened at the high leg and mid-thigh. With the exception of the CAT7 and the SOFTT-W at the mid-thigh, no windlass TQ was successfully tightened at any extremity location on the infant. The SWAT-T was successfully tightened over all sites of all CPR manikins except the infant. No windlass TQ was able to tighten on PVC pipe 5.75” circumference or smaller (age < 24 months upper extremity). All windlass TQs were tightened and secured on the 13.25” and 15.5” circumference PVC pipes (age 7–12 years lower extremity, age >13 years upper extremity). The SWAT-T was tightened on all PVC pipes.DiscussionThe current study suggests that commercial windlass TQs can be applied to upper and lower extremities of children aged 5 years and older at the 50%th percentile for limb circumference. In younger children, windlass TQ efficacy is variable. Further study is required to better understand the limitations of TQs in the youngest children, and to determine actual hemorrhage control efficacy.
Anticonvulsant Prophylaxis and Steroid Use in Adults With Metastatic Brain Tumors: ASCO and SNO Endorsement of the Congress of Neurological Surgeons Guidelines
Chang, Susan M. , Messersmith, Hans , Ahluwalia, Manmeet S. , Gaspar, Laurie E., Gatson, Na Tosha , Khasraw, Mustafa , Lassman, Andrew B. , Maués, Julia , Mrugała, Maciej M. , Raizer, Jeffrey J. , Schiff, David , Stevens, Glen , Sumrall, Ashley , Bent, Martin J. van den , Vogelbaum, Michael A. , van den Bent, Martin J , Khasraw, Mustafa , Gatson, Na Tosha N , Messersmith, Hans , Sumrall, Ashley , Ahluwalia, Manmeet S , Chang, Susan Marina , Andrews, David William , Brastianos, Priscilla K. , Jordan, Justin T.

Mayo Clinic

Journal of Clinical Oncology | March 18, 2019 | Volume: 37 | Issue: 13 | Pages: 1130-1135

10.1200/jco.18.02085 | PMID 30883246 Get It

PURPOSE The Congress of Neurological Surgeons (CNS) has developed a series of guidelines for the treatment of adults with metastatic brain tumors, including systemic therapy and supportive care topics. ASCO has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. METHODS Two CNS guidelines were reviewed for developmental rigor by methodologists, and an independent multidisciplinary Expert Panel was formed to review the content and assess agreement with the recommendations. The Expert Panel voted to endorse the two guidelines, and ASCO and Society for Neuro-Oncology (SNO) independently reviewed and approved the ASCO/SNO guideline endorsement. RESULTS The ASCO/SNO Expert Panel determined that the recommendations from the CNS anticonvulsants and steroids guidelines, published January 9, 2019, are clear, thorough, and based on the most relevant scientific evidence. ASCO/SNO endorsed these two CNS guidelines with minor alterations. RECOMMENDATIONS Key recommendations include the following: prophylactic antiepileptic drugs were not recommended for routine use; and corticosteroids, specifically dexamethasone, were recommended for temporary symptomatic relief in patients with neurologic symptoms and signs related to mass effect from brain metastases. Additional information is available at www.asco.org/neurooncology-guidelines .
AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth.
Hu, Brian , Fairey, Adrian, Madhav, Anisha, Li, Meng , Groshen, Susan , Stephens, Craig, Virk, Navneet, Martin, Sue Ellen , Erho, Nicholas , Jenkins, Robert B. , Xu, Tong , Xu, Yucheng, Goldkorn, Amir , Yang, Dongyun , Kim, Philip, Wang, Lina , Davicioni, Elai , Den, Robert B. , Gill, Inderbir S. , Quinn, David I

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e16092-e16092

10.1200/jco.2015.33.15_suppl.e16092 Get It

Programmed death-ligand 1 (PD-L1) expression in small bowel adenocarcinomas (SBA).
Smyrk, Thomas C. , Harrington, Susan M. , Pedersen, Katrina S. , McWilliams, Robert R.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 3619-3619

10.1200/jco.2015.33.15_suppl.3619 Get It

Results of NRG oncology/RTOG 9813: A phase III randomized study of radiation therapy (RT) and temozolomide (TMZ) versus RT and nitrosourea (NU) therapy for anaplastic astrocytoma (AA).
Chang, Susan M. , Cairncross, J. Gregory , Bahary, Jean-Paul , Dolinskas, Carol A., Aldape, Kenneth , Schiff, David , Jaeckle, Kurt A. , Brown, Paul D. , Barger, Geoffrey, Werner‐Wasik, Maria, Brachman, David, Peñas-Prado, Marta , Robins, H. Ian, Bélanger, Karl, Schultz, Christopher J. , Zhang, Peixin, Gilbert, Mark R. , Chakravarti, Arnab , Shih, Helen A. , Mehta, Minesh P.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 2002-2002

10.1200/jco.2015.33.15_suppl.2002 Get It

Adjuvant aromatase inhibitor adherence based on the Morisky Medication Adherence Scale and identification of predictors to adherence.
Rosenblatt, Paula , Goloubeva, Olga, Bellavance, Emily, Chumsri, Saranya , Nichols, E.M. , Feigenberg, Steven J. , Tait, Nancy, Tkaczuk, Katherine H. R., Kesmodel, Susan B , Bao, Ting , Heiss, Brian L.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 555-555

10.1200/jco.2015.33.15_suppl.555 Get It

Abstract P421: Cardiovascular Death Trends in Minnesota From 2000-2017
Weston, Susan A., Manemann, Sheila M., Killian, Jill M. , Dugani, Chandrasagar, Roger, Véronique L. , Gerber, Yariv , Bielinski, Suzette J. , Chamberlain, Alanna M.

Mayo Clinic

Circulation | March 6, 2019 | Volume: 139 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.139.suppl_1.p421 Get It

Background: The decline in cardiovascular disease (CVD) mortality in the United States noted since the mid 1970s has recently leveled off. This has generated concern and a need for further analyses to understand geographic variation, cause-specific deaths, location of death, and age-specific trends. Methods: Death certificate data obtained from the Minnesota Department of Health were used for analysis. The American Heart Association (AHA) classification was applied to the underlying cause of death to generate the following CVD categories: coronary heart disease (CHD), non-CHD diseases of the heart, and non-cardiac circulatory diseases. Temporal trends in death rates were explored by negative binomial regression, which enables estimates of age- and sex-adjusted average annual percentage changes (AAPCs). Differences in AAPCs between 2000-2009 and 2010-2017 were tested overall and across demographic, CVD, and location of death categories. Results: CVD mortality rates, which were declining in 2000-2009, have leveled off in 2010-2017 (Table). These trends were observed across all subgroups. After adjusting for sex, the age group that drove the decline in rates from 2000-2009 was the 65-84 year old group, which experienced no change in rates from 2010-2017. Across CVD categories, after adjusting for age and sex, the decline in rates from 2000-2009 was largely attributable to steep reductions in CHD and non-cardiac circulatory diseases, with lesser reduction in non-CHD diseases of the heart. In 2010-2017, CHD and non-cardiac circulatory diseases rates showed no change, whereas the rate of non-CHD diseases of the heart increased. The rates for in- and out-of-hospital deaths improved in 2000-2009 with no further improvement observed in 2010-2017. Conclusions: CVD mortality rates are no longer declining in Minnesota, paralleling national trends. These trends are particularly concerning for non-CHD diseases of the heart.
Abstract P157: Association of Rurality With Death in Patients With Heart Failure: a Community Study
Manemann, Sheila M., Rutten, Lila Finney, Fabbri, Matteo, Weston, Susan A., Jiang, Ruoxiang , Roger, Véronique L. , Sauver, Jennifer L. St. , Chamberlain, Alanna M.

Mayo Clinic

Circulation | March 6, 2019 | Volume: 139 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.139.suppl_1.p157 Get It

Background: Previous studies have indicated that living in a rural or non-urban area may be associated with poor health outcomes. However, data on rurality and death in heart failure (HF) are scarce. Methods: Residents from 11 southeast MN counties with a first-ever code for HF (including codes ICD-9 428 and ICD-10 I50) between 1/1/2013 and 12/31/2016 were identified. Resident address was geo-coded and classified according to the Rural-Urban Commuting Area (RUCA) codes, which classifies US census tracts to measure population density, urbanization and daily commuting. Rurality was defined as living in a non-metropolitan area. Cox proportional hazards regression was used to determine the association between living in a rural vs. urban area and death. Results: Among 6,996 patients (mean age 73 years, 52% male), 54% of patients lived in a rural area. These patients were older and had a lower level of educational attainment and comorbidity burden (p<0.001). After a mean (SD) follow-up of 2.9 (1.3) years, 1,856 deaths occurred. Living in a rural area was univariately associated with a higher risk of death (HR 1.20, 95% CI: 1.09-1.31; Table). After adjustment for age, sex, education status and comorbidity burden, rurality remained associated with an increased risk of death (HR 1.15; 95% CI: 1.04-1.27). Conclusions: Among patients with HF, living in a rural area is associated with an increased risk of death. Further study to identify and address the mechanisms through which rural residence influences mortality in patients with HF is needed.
Abstract MP17: Comorbidity Type and Risk of Hospitalization and Death in Patients With Atrial Fibrillation
Jiang, Ruoxiang , Weston, Susan A., Bengtson, Lindsay G.S. , Claxton, J’Neka S. , MacLehose, Richard F. , Roger, Véronique L. , Chamberlain, Alanna M. , Alonso, Álvaro , Noseworthy, Peter A. , Lutsey, Pamela L. , Chen, Lin , O’Neal, Wesley T. , Norby, Faye L.

Mayo Clinic

Circulation | March 6, 2019 | Volume: 139 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.139.suppl_1.mp17 Get It

Background: Multimorbidity is common in atrial fibrillation (AF); however, the impact of the number and type of comorbid conditions on death and hospitalizations is uncertain. Methods: The prevalence of 17 chronic conditions was obtained in 1430 patients with incident AF from 2000-2010 from Olmsted County, MN. Chronic conditions were ascertained electronically prior to AF and were classified into 3 groups: cardiovascular (CV), other physical, and mental. All hospitalizations and deaths were obtained through 12/31/2014. Associations of the number and type of condition and each individual condition with hospitalizations and death were determined using Andersen-Gill and Cox regression, respectively. Results: Among the 1430 patients with AF (median age 76 years, 48.6% men), the mean (SD) number of chronic conditions was 4.7 (2.7). A total of 4496 hospitalizations and 812 deaths occurred over a mean (SD) follow-up of 5.4 (4.1) years. An increase in the number of conditions of each type was associated with increased risks of death and hospitalizations (Table). Mental conditions (which included depression, anxiety, dementia, schizophrenia, and substance abuse) exhibited the strongest association with death, whereas other physical conditions exhibited the strongest association with hospitalizations. Individual predictors of death included heart failure (HF), hypertension, chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD), depression, dementia, and substance abuse. Predictors of hospitalizations included HF, coronary artery disease, diabetes, COPD, CKD, arthritis, osteoporosis, and substance abuse. Conclusions: Patients with AF have many comorbid conditions which are associated with death and hospitalizations. Although conditions of each type were associated with outcomes, mental conditions exhibited strongest association with death. These data highlight the importance of management of not only CV comorbidities but other physical and mental comorbidities in patients with AF.